A Feasibility and Safety Study of a Novel Human Decellularized Dermal Matrix to Accelerate Healing of Neuropathic Diabetic Foot Ulcers in People With Type 1 and Type 2 Diabetes

Published:April 06, 2022DOI:



      The purpose of this study was to determine the feasibility and safety of a novel decellularized dermal matrix (DDM) for the treatment of chronic diabetic foot ulcers (DFUs).


      An interventional, single-arm, prospective study of DDM for DFU treatment was conducted in 2 Canadian centres from July 1, 2016, to May 30, 2017. Individuals ≥18 years of age with an active DFU of ≥2 weeks and ulcer area ≥1 cm2 before debridement and who consented to participate were enrolled in this clinical trial.


      A total of 11 patients were enrolled, with 9 patients (82%) having achieved 100% closure between 2 and 8 weeks. The mean and median times to wound closure for these patients were 3.3 and 2.5 weeks, respectively. The mean and median reductions in wound area at 4 weeks posttreatment were 87% and 100%, respectively. The proportion of patients having achieved complete healing at 12 weeks was 82%. All patients received only 1 DDM application to achieve these results. There were no adverse events related to use of the product. No cases of recurrence during a 1-year follow-up after completion of the study were reported for patients who achieved wound closure.


      These findings provide evidence that this DDM may be safe and effective for the treatment of chronic, hard-to-heal neuropathic DFUs. Specifically, DDM demonstrated the potential to accelerate healing of DFUs when compared with reported times of 8 to 12 weeks required to achieve closure using the current standard of care.



      L’objectif de la présente étude était de déterminer la faisabilité et l’innocuité de la nouvelle matrice dermique décellularisée (MDD) dans le traitement des ulcères chroniques du pied diabétique (UPD).


      Nous avons mené une étude prospective interventionnelle à volet unique sur la MDD dans le traitement des UPD dans 2 établissements canadiens du 1er juillet 2016 au 30 mai 2017. Nous avons inscrit à cette étude clinique les individus de ≥ 18 ans, qui avaient un UPD actif depuis ≥ 2 semaines, dont la surface était de ≥ 1 cm2 avant le débridement, et qui consentaient à participer à l’étude.


      Nous avons inscrit un total de 11 patients, dont 9 (82 %) avaient vu leur plaie se refermer à 100 % entre 2 et 8 semaines. Les temps moyen et médian de la fermeture de la plaie de ces patients étaient respectivement de 3,3 et de 2,5 semaines. Les réductions moyenne et médiane de la surface de la plaie 4 semaines après le traitement étaient respectivement de 87 % et de 100 %. Le pourcentage de patients qui avaient eu une guérison complète après 12 semaines était de 82 %. Tous les patients ont reçu 1 seule application de MDD pour obtenir ces résultats. Il n’y a eu aucun événement indésirable associé à l’utilisation du produit. Aucun cas de récidive n’a été signalé jusqu’à 1 an après la fin de l’étude chez les patients dont la plaie s’était refermée.


      Ces résultats montrent l’innocuité et l’efficacité de cette MDD dans le traitement des UPD neuropathiques chroniques difficiles à guérir. Particulièrement, la MDD a démontré son potentiel à accélérer la guérison des UPD lorsqu’on la compare aux normes actuelles en matière de soins qui requièrent de 8 à 12 semaines pour parvenir à la fermeture de la plaie.


      Mots clés

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Guariguata L.
        • Whiting D.R.
        • Hambleton I.
        • Beagley J.
        • Linnenkamp U.
        • Shaw J.E.
        Global estimates of diabetes prevalence for 2013 and projections for 2035.
        Diabetes Res Clin Prac. 2014; 103: 137-149
        • Diabetes Canada
        New diabetes rates released with urgent plea for governments to implement national diabetes strategy. 2019.
        • Singh N.
        • Armstrong D.G.
        • Lipsky B.A.
        Preventing foot ulcers in patients with diabetes.
        JAMA. 2005; 293: 217-228
        • Boulton A.J.
        • Vileikyte L.
        • Fau-Ragnarson-Tennvall G.
        • Apelqvist J.
        The global burden of diabetic foot disease.
        Lancet. 2005; 366: 1719-1724
        • Everett E.
        • Mathioudakis N.
        Update on management of diabetic foot ulcers.
        Ann NY Acad Sci. 2018; 1411: 153-165
        • Reiber G.E.
        The epidemiology of diabetic foot problems.
        Diabet Med. 1996; 13: S6-S11
        • Robbins J.M.
        • Strauss G.
        • Aron D.
        • Long J.
        • Kuba J.
        • Kaplan Y.
        Mortality rates and diabetic foot ulcers: Is it time to communicate mortality risk to patients with diabetic foot ulceration?.
        J Am Podiatr Med Assoc. 2008; 98: 489-493
        • Cancer Ontario
        Relative survival: Cancer care Ontario.
        • Robertshaw L.
        • Robertshaw D.A.
        • Whyte I.
        Audit of time taken to heal diabetic foot ulcers.
        Practical Diabetes Int. 2001; 18: 6-9
        • Sheehan P.
        • Jones P.
        • Caselli A.
        • et al.
        Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial.
        Diabetes Care. 2003; 26: 1879-1882
        • Lu S.H.
        • McLaren A.M.
        Wound healing outcomes in a diabetic foot ulcer outpatient clinic at an acute care hospital: A retrospective study.
        J Wound Care. 2017; 26: S4-S11
        • Hicks C.W.
        • Selvarajah S.
        • Mathioudakis N.
        • et al.
        Burden of infected diabetic foot ulcers on hospital admissions and costs.
        Ann Vasc Surg. 2016; 33: 149-158
        • Coerper S.
        • Beckert S.
        • Küper M.A.
        • et al.
        Fifty percent area reduction after 4 weeks of treatment is a reliable indicator for healing---analysis of a single-center cohort of 704 diabetic patients.
        J Diabetes Complications. 2009; 23: 49-53
        • Snyder R.J.
        • Cardinal M.
        • Dauphiné D.M.
        • Stavosky J.
        A post-hoc analysis of reduction in diabetic foot ulcer size at 4 weeks as a predictor of healing by 12 weeks.
        Ostomy Wound Manage. 2010; 56: 44-50
        • Lavery
        • et al.
        Risk factors for foot infections in individuals with diabetes.
        Diabetes Care. 2006; 29: 1288-1293
        • Mansbridge J.
        Tissue-engineered skin substitutes.
        Expert Opin Biol Ther. 2002; 2: 25-34
        • Orenstein S.
        • Quao Y.
        • Kaur M.
        • Klueh U.
        • Kreutzer D.
        • Novitsky Y.
        Human monocyte activation by biologic and biodegradable meshes in vitro.
        Surg Endosc. 2009; 24: 805-811
        • Faleris J.A.
        • Hernandez R.M.C.
        • Wetzel W.
        • Dodds R.
        • Greenspan D.C.
        In-vivo and in-vitro histological evaluation of two commercially available acellular dermal matrices.
        Hernia. 2011; 15: 147-156
        • Lancaster G.A.
        • Dodd S.
        • Williamson P.R.
        Design and analysis of pilot studies: Recommendations for good practice.
        J Eval Clin Pract. 2004; 10: 307-312
        • Thabane L.
        • Ma J.
        • Chu R.
        • et al.
        A tutorial on pilot studies: The what, why and how.
        BMC Med Res Methodol. 2010; 10: 1
        • Billingham S.A.
        • Whitehead A.L.
        • Julious S.A.
        An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database.
        BMC Med Res Methodol. 2013; 20: 104
        • Woodbury M.G.
        • Houghton P.E.
        • Campbell K.E.
        • Keast D.H.
        Development, validity, reliability, and responsiveness of a new leg ulcer measurement tool.
        Adv Skin Wound Care. 2004; 17: 187-196
      1. NIH Image. Online manual (version 1.61).
        • Agency for Healthcare Research and Quality
        Technology assessment: Skin substitutes for treating chronic wounds.
        • Government of Canada
        Clinical safety data management definitions and standards for expedited reporting ICH topic E2A: Guidance for industry.
        • Dinh T.L.
        • Veves A.
        The efficacy of Apligraf in the treatment of diabetic foot ulcers.
        Plast Reconstr Surg. 2006; 117 (152S–7S; discussion 158S–9S)
        • Edmonds M.
        Apligraf in the treatment of neuropathic diabetic foot ulcers.
        Int J Low Extrem. 2009; 8: 11-18
        • Marston W.A.
        • Hanft J.
        • Norwood P.
        • Pollak R.
        The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers.
        Diabetes Care. 2003; 26: 1701
        • Reyzelman A.
        • Crews R.T.
        • Moore J.C.
        • et al.
        Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: A prospective, randomised, multicentre study.
        Int Wound J. 2019; 6: 196-208
        • Zelen C.M.
        • Gould L.
        • Serena T.E.
        • Carter M.J.
        • Keller J.
        • Li W.W.
        A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers.
        Int Wound J. 2015; 12: 724-732
        • Yonehiro L.
        • Burleson G.
        • Sauer V.
        Use of a new acellular dermal matrix for treatment of nonhealing wounds in the lower extremities of patients with diabetes.
        Wounds. 2013; 25: 340-344
        • Walters J.
        • Cazzell S.
        • Pham H.
        • Vayser D.
        • Reyzelman A.
        Healing rates in a multicenter assessment of a sterile, room temperature, acellular dermal matrix versus conventional care wound management and an active comparator in the treatment of full-thickness diabetic foot ulcers.
        Eplasty. 2016; 16: e10
        • Winters C.
        • Brigido S.
        • Liden B.
        • Simmons M.
        • Hartman J.
        • Wright M.
        A multicenter study involving the use of a human acellular dermal regenerative tissue matrix for the treatment of diabetic lower extremity wounds.
        Adv Skin Wound Care. 2008; 21: 375-381
        • Cazzell S.
        • Vayser D.
        • Pham H.
        • et al.
        A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator.
        Wound Repair Regen. 2017; 25: 483-497
        • Tettelbach W.
        • Cazzell S.
        • Reyzelman A.M.
        • Sigal F.
        • Caporusso J.M.
        • Agnew P.S.
        A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics.
        Int Wound J. 2019; 16: 19-29